1. Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea.
- Author
-
Da Silva K, Guilly S, Thirion F, Le Chatelier E, Pons N, Roume H, Quinquis B, Ehrlich SD, Bekkat N, Mathiex-Fortunet H, Sokol H, and Doré J
- Subjects
- Adolescent, Adult, Bacteria classification, Bacteria genetics, Chronic Disease therapy, Female, Humans, Male, Middle Aged, Young Adult, Diarrhea drug therapy, Feces microbiology, Gastrointestinal Microbiome drug effects, Gastrointestinal Microbiome genetics, Metagenome, Silicates therapeutic use
- Abstract
Background: Diosmectite, a natural colloidal clay, has been used worldwide for a number of approved indications, including the treatment of chronic functional diarrhea. Here, we used high-resolution whole metagenome shotgun sequencing to assess the impact of a 5 weeks administration of diosmectite (3 g/sachet, 3 sachets/day) on the fecal microbiota of 35 adults with functional chronic diarrhea., Results: Gut microbiota was not impacted by diosmectite administration. In particular, richness remained stable and no microbial species displayed a significant evolution. Segregating patients either by diosmectite response (non responder, early responder, late responder) or by nationality (Great-Britain or Netherlands) yielded the same results., Conclusion: We concluded that no microbiota-related physiological alterations are expected upon long-term treatment with diosmectite., Trial Registration: Clinicaltrials.gov NCT03045926., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF